Synlogic, INC 10-Q quarterly reports

Synlogic reports a net loss for the quarter and six months ended June 30, 2026, while advancing a significant merger with Caldera Therapeutics.

Synlogic Inc. reported a net income of $681,000 for the first quarter of 2026, a significant increase from the prior year, as the company continues its strategic review process.

Synlogic, Inc. reported a significantly reduced net loss for the nine months ended September 30, 2025, as it continues to evaluate strategic alternatives following the discontinuation of its lead clinical trial.

Synlogic reported a significantly reduced net loss and cash burn in Q2 2025 as it continues to evaluate strategic alternatives following the discontinuation of its lead clinical trial.

Synlogic reports a net income of $0.3 million for Q1 2025, driven by a gain in the fair value of purchase warrants, while the company continues to explore strategic alternatives.

Synlogic discontinues its pivotal Phase 3 trial for labafenogene marselecobac (SYNB1934) and initiates a strategic review process, including potential merger or sale, while significantly reducing its workforce.

Synlogic discontinued its pivotal Phase 3 trial for labafenogene marselecobac (SYNB1934) and is exploring strategic alternatives, including a potential merger or sale of the company, following a corporate restructuring.

Synlogic discontinued its pivotal Phase 3 trial for labafenogene marselecobac (SYNB1934) and initiated a strategic review, including potential merger or sale, while undergoing a significant corporate restructuring.